Every dollar spent on COVID vaccine development and distribution generated between $59 and $809 in economic value, ...
Real-world analysis of more than 294,000 U.S. Veterans aged 65 and older found mNEXSPIKE was associated with a 35.9% ...
The LP.8.1-adapted BNT162b2 COVID-19 vaccine elicited a strong immune response and showed an acceptable safety profile in high-risk patients.
A new COVID-19 variant, PJ.2.1, is attracting attention after being detected across several countries, including parts of ...
New Scientist on MSN
The economic benefits of the COVID vaccines may be double what we thought
The global health and economic benefits of the covid-19 vaccines were thought to have reached up to $38 trillion in their ...
Two routine deltoid injections, one rare shoulder complication, and differences across vaccine formulations that may hint at ...
Nuvaxovid ®, a protein-based, non-mRNA COVID-19 vaccine, will be available in 10 provinces and one territory for the fall 2026-2027 respiratory season A protein-based, non-mRNA vaccine that has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results